Showing results (321-330 of 337) with videos related to
Sort By:
Pageof 34
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 19, 2024
Paclitaxel, Ifosfamide, and Cisplatin as Initial Salvage Chemotherapy for Germ Cell Tumors: Long-Term Follow-Up and Outcomes for Favorable- and Unfavorable-Risk DiseaseJack P Gleeson, Andrea Knezevic, Maria Bromberg, et al.Breast Cancer Research and Treatment|June 1, 2017
Social well-being is associated with less pro-inflammatory and pro-metastatic leukocyte gene expression in women after surgery for breast cancerDevika R Jutagir, Bonnie B Blomberg, Charles S Carver, et al.Journal of Consulting and Clinical Psychology|May 5, 2015
Brief cognitive-behavioral and relaxation training interventions for breast cancer: A randomized controlled trialLisa M Gudenkauf, Michael H Antoni, Jamie M Stagl, et al.Proceedings of the National Academy of Sciences of the United States of America|July 16, 2014
Copy number alteration burden predicts prostate cancer relapseHaley Hieronymus, Nikolaus Schultz, Anuradha Gopalan, et al.Proceedings of the National Academy of Sciences of the United States of America|August 6, 2021
Rapid interrogation of cancer cell of origin through CRISPR editingWeiran Feng, Zhen Cao, Pei Xin Lim, et al.Cell|January 16, 2007
Ubiquitination regulates PTEN nuclear import and tumor suppressionLloyd C Trotman, Xinjiang Wang, Andrea Alimonti, et al.The Oncologist|February 15, 2021
Four Cycles of Etoposide plus Cisplatin for Patients with Good-Risk Advanced Germ Cell TumorsSamuel A Funt, Deaglan J McHugh, Stephanie Tsai, et al.Nature Communications|August 21, 2021
Defining the therapeutic selective dependencies for distinct subtypes of PI3K pathway-altered prostate cancersNinghui Mao, Zeda Zhang, Young Sun Lee, et al.Cancer Discovery|February 6, 2015
Suppression of CHK1 by ETS Family Members Promotes DNA Damage Response Bypass and TumorigenesisAndrea Lunardi, Shohreh Varmeh, Ming Chen, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 12, 2025
Oncologic outcomes of retroperitoneal lymph node dissection following first-line chemotherapy for metastatic non-seminomatous germ-cell tumorsR S Matulewicz, F Baky, N Liso, et al.Pageof 34